Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Immunity offers exploitation development tools, vulnerability assessment tools, and remote control technologies. The company delivers consulting services such as adversary simulation, application vulnerability analysis, digital executive protection, exploit development and reverse engineering, network security assessment, penetration testing, process review, source code analysis, web application testing, and wireless security assessment. It also serves as an information hub within the global security community by hosting the DailyDave mailing list and serving as a source for analysis and opinion on new threats.The company’s products include Canvas, Debugger, El Jefe, Innuendo, Swarm, and Silica.Immunity delivers products and services to Fortune and Global 500 companies and smaller organizations across all vertical markets. It also serves government departments from all over the world.Immunity was founded in 2002 and is headquartered in Miami Beach, Florida with presence in Washington, D.C.; and international ...

Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College. Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'golden triangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Part of GemVax & KAEL Co., Ltd., Gemvax AS is a company headquartered in Porsgrunn, Norway, that develops and manufactures pharmaceuticals. It was founded by Mona Elisabeth M��ller. Gemvax AS was acquired by VaxOnco, Inc. from Pharmexa An on October 30, 2008.\nThe company says this about itself: Based in Seoul, Korea, GemVax Group operates in two main areas: environmental protection and biopharmaceutical drug development. The biopharmaceutical arm, GemVax & KAEL was formed in 1998 and comprises Samsung Pharm, GemVax and FEELingK. It has brought to the market the first-in-class immunotherapeutic drug RIAVAX��inj for pancreatic cancer. Based on telomerase modification, the company's lead candidate GV1001 also has potential other indications in cancer and neurodegenerative diseases.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Norsk Hydro ASA engages in producing and supplying alumina and primary aluminum. It operates through the following segments: Hydro Bauxite & Alumina, Hydro Aluminium Metal, Hydro Extrusions, Hydro Energy, Hydro Metal Markets, and Other. The Hydro Bauxite & Alumina segment includes bauxite mining activities, production of alumina and related commercial activities, primarily the sale of alumina. The Hydro Aluminium Metal segment includes primary aluminium production and casting activities. The Hydro Extrusions segment delivers products within extrusion profiles, building systems and precision tubing, and is operating several recycling facilities, both integrated with its extrusion plants and separate plants. The Hydro Energy includes operating and commercial responsibility for Hydro's power stations in Norway, a trading and wholesale business in Brazil, and energy sourcing for Hydro’s world-wide operations. The Hydro Metal Markets includes all sales activities relating to products from primary metal plants and operational responsibility for stand-alone recyclers as well as physical and financial metal trading activities. The company was founded on December 2, 1905 and is headquartered in Oslo, Norway.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Suzhou Proda Biotechnology Co., Ltd., established on 2012-12-22, Business scope includes biomedicine,Health products,food,cosmetic,medical instruments,Non-hazardous chemical products,Research and development of sewage treatment technology,Technical cooperation,technical consulting,technology transfer;Sales:Non-hazardous chemical products,Class I medical device,cosmetic.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women��s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer��s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

GenPat77 Pharmacogenetics AG researches and develops immune modulatory therapeutics for immune mediated diseases. The company was founded in 1998 and is headquartered in Berlin, Germany.

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.

Aeras is a global nonprofit biotech with a mission to develop new tuberculosis vaccines that are affordable and accessible to all who need them. Aeras has capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field, Aeras has sponsored and conducted over 25 clinical vaccine trials enrolling thousands of subjects, and is a key partner in six active clinical development programs. Aeras has approximately 160 employees, with offices in Rockville, Maryland; Cape Town, South Africa; and Beijing, China.

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.